Article Sidebar

PDF
Date Published: 25/12/2023
Online Published: 25/12/2023
Abstract Views: 79
Views PDF: 71
DOI: https://doi.org/10.58490/ctump.2023i69.1969
Issue
No. 69 (2023)
Section
Article
How to Cite
Quach , H. L., & Tran , H. T. (2023). STUDY OF THE SITUATION AND RESULTS OF OUTPATIENT TREATMENT FOR BENIGN PROSTATIC HYPERPLASIA AT CA MAU GENERAL HOSPITAL. Cantho Journal of Medicine and Pharmacy, 69, 23-29. https://doi.org/10.58490/ctump.2023i69.1969

STUDY OF THE SITUATION AND RESULTS OF OUTPATIENT TREATMENT FOR BENIGN PROSTATIC HYPERPLASIA AT CA MAU GENERAL HOSPITAL

Huu Loi Quach 1,, Huynh Tuan Tran 2
1 Ca Mau General Hospital
2 Can Tho University of Medicine and Pharmacy

Main Article Content

Abstract

Background: Benign prostatic hyperplasia is a common disease in men. Disease situation, inappropriate treatment indications, drug abuse, and the degree of adherence to treatment has not been evaluated. That is reason why we have proceeded this research. Objectives: To determine the rate of symptoms, disease severity, quality of life, some laboratory factors and results of benign prostatic hyperplasia outpatient treatment. Materials and methods: This was a prospective, crosssectional study, 106 outpatients with benign prostatic hyperplasia from 7/2021 to 6/2022 in Ca Mau General Hospital. Results: Average age was 71.4±8.3, the most common reason for admission was dysuria 59.4%. Before surgery, average IPSS was 19.5±5.1, average QoL was 4.8±1.0, average prostate volume was 43.3±13.6mL, total blood PSA was 4.1±3.4ng/mL. There month after surgery, average IPSS decreased 6.9, average QoL decreased 2.3. The rate of adherence to treatment was 94.3%. Adverse effects: fatigue (3.8%), dizziness (9.6%), headache (4.7%), orthostatic hypotension (3.8%). Conclusions: Drug therapy and lifestyle changes had a rate of adherence in the treatment and results of treatment is good; Clinical symptoms and quality of life improved compared to before treatment.

Article Details

Keywords

Benign prostatic hyperplasia, drug therapy, lifestyle changes

References

1. Hội Tiết Niệu-Thận học Việt Nam. Hướng dẫn xử trí tăng sinh lành tính tiền liệt tuyến, Nhà xuất bản Y học, Hà Nội. 2019.
2. Miernik A, Gratzke C., Current Treatment for Benign Prostatic Hyperplasia, Dtsch Arztebl Int, 2020. 117(4), 843-854. DOI:10.3238/arztebl.2020.0843.
3. Das K, Buchholz N., Benign prostate hyperplasia and nutrition, Clin Nutr ESPEN, 2019. 33, 511. DOI:10.1016/j.clnesp.2019.07.015.
4. Đàm Văn Cương và cộng sự. Nghiên cứu đặc điểm lâm sàng, cận lâm sàng và đánh giá kết quả điều trị bệnh nhân tăng sinh tuyến tiền liệt bằng alfuzosin HCL tại Bệnh viện Trường Đại học Y Dược Cần Thơ, Tạp chí Y học Thành phố Hồ Chí Minh. 2017. 21(6), 114-116.
5. Elhilali M, Emberton M, Matzkin H, et al., Longterm efficacy and safety of alfuzosin 10 mg once daily: a 2-year experience in “real-life” practice., BJU Int,97, 2006. 513-519. DOI:10.1111/j.1464-410X.2005.05962.x.
6. A. Mari, A. Antonelli, L. Cindolo, F. Fusco, A. Minervini, De Nunzio, Alfuzosin for the medical treatment of benign prostatic hyperplasia and lower urinary tract symptoms: a systematic review of the literature and narrative synthesis, Therapeutic advances in urology, 2021. 13. DOI:10.1177/1756287221993283.
7. Vallancien G, Emberton M, Alcaraz A, et al. Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in reallife practice, BJU Int, 2008. 101, 847-852. DOI:10.1111/j.1464-410X.2008.07458.x.
8. Lukacs B, Grange JC, Comet D (2000), One-year follow-up of 2829 patients with moderate to severe lower urinary tract symptoms treated with alfuzosin in general practice according to IPSS and a health-related quality-of-life questionnaire. BPM group in general practice, Urology, 55, 540-546. DOI:10.1016/s0090-4295(99)00539-7.
9. The Italian Alfuzosin co-operative group (2000), Safety, efficacy and impact on patients’ quality of life of a long-term treatment with the alpha(1)-blocker alfuzosin in symptomatic patients with BPH, Eur Urol, 37, 680-686. DOI: 10.1159/000020218.